Iodine-125 seeds combined with anlotinib in the treatment of recurrent retroperitoneal liposarcoma after surgery: a case report
Retroperitoneal liposarcoma (RPLS) is a rare malignant mesenchymal tumor originating in the retroperitoneal space. It is characterized by a low incidence, poorly understood etiology and pathogenesis, and diverse imaging and pathological manifestations. The malignancy of RPLS varies significantly amo...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1540868/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850140525163708416 |
|---|---|
| author | Gaoyan Tang Yuping Zhang Wenjuan Meng Shoubin Zhong Hui Feng Guohua Yu Shuzhen Liu Rui Li |
| author_facet | Gaoyan Tang Yuping Zhang Wenjuan Meng Shoubin Zhong Hui Feng Guohua Yu Shuzhen Liu Rui Li |
| author_sort | Gaoyan Tang |
| collection | DOAJ |
| description | Retroperitoneal liposarcoma (RPLS) is a rare malignant mesenchymal tumor originating in the retroperitoneal space. It is characterized by a low incidence, poorly understood etiology and pathogenesis, and diverse imaging and pathological manifestations. The malignancy of RPLS varies significantly among cases. Currently, surgical resection remains the primary treatment for primary retroperitoneal liposarcoma; however, the disease is associated with a high and rapid recurrence rate, which severely impacts patient prognosis. This study presents a case of recurrent retroperitoneal liposarcoma treated with iodine-125 seed implantation following surgical intervention. Due to the large tumor size, high risk of postoperative recurrence, and the challenges of accurately targeting postoperative radiotherapy, surgical re-intervention was deemed unsuitable. Consequently, a comprehensive treatment plan involving iodine-125 seed implantation combined with anlotinib therapy was formulated. The patient achieved stable disease control over a 3-year follow-up period, demonstrating the potential efficacy of this combined therapeutic approach. This case highlights the antitumor potential of iodine-125 seed implantation combined with anlotinib in the management of retroperitoneal liposarcoma, particularly in cases where surgical options are limited. |
| format | Article |
| id | doaj-art-e8a2bbdb8ce14d239f3326fee7d96869 |
| institution | OA Journals |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-e8a2bbdb8ce14d239f3326fee7d968692025-08-20T02:29:46ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-04-011510.3389/fonc.2025.15408681540868Iodine-125 seeds combined with anlotinib in the treatment of recurrent retroperitoneal liposarcoma after surgery: a case reportGaoyan Tang0Yuping Zhang1Wenjuan Meng2Shoubin Zhong3Hui Feng4Guohua Yu5Shuzhen Liu6Rui Li7Department of Oncology, Weifang People’s Hospital (The First Affiliated Hospital of Shandong Second Medical University), Weifang, ChinaCenter for Precision Pathological Diagnosis, Weifang People’s Hospital (The First Affiliated Hospital of Shandong Second Medical University), Weifang, ChinaDepartment of Oncology, Weifang People’s Hospital (The First Affiliated Hospital of Shandong Second Medical University), Weifang, ChinaDepartment of Oncology, Weifang People’s Hospital (The First Affiliated Hospital of Shandong Second Medical University), Weifang, ChinaDepartment of Oncology, Weifang People’s Hospital (The First Affiliated Hospital of Shandong Second Medical University), Weifang, ChinaDepartment of Oncology, Weifang People’s Hospital (The First Affiliated Hospital of Shandong Second Medical University), Weifang, ChinaDepartment of Oncology, Weifang People’s Hospital (The First Affiliated Hospital of Shandong Second Medical University), Weifang, ChinaDepartment of Oncology, Weifang People’s Hospital (The First Affiliated Hospital of Shandong Second Medical University), Weifang, ChinaRetroperitoneal liposarcoma (RPLS) is a rare malignant mesenchymal tumor originating in the retroperitoneal space. It is characterized by a low incidence, poorly understood etiology and pathogenesis, and diverse imaging and pathological manifestations. The malignancy of RPLS varies significantly among cases. Currently, surgical resection remains the primary treatment for primary retroperitoneal liposarcoma; however, the disease is associated with a high and rapid recurrence rate, which severely impacts patient prognosis. This study presents a case of recurrent retroperitoneal liposarcoma treated with iodine-125 seed implantation following surgical intervention. Due to the large tumor size, high risk of postoperative recurrence, and the challenges of accurately targeting postoperative radiotherapy, surgical re-intervention was deemed unsuitable. Consequently, a comprehensive treatment plan involving iodine-125 seed implantation combined with anlotinib therapy was formulated. The patient achieved stable disease control over a 3-year follow-up period, demonstrating the potential efficacy of this combined therapeutic approach. This case highlights the antitumor potential of iodine-125 seed implantation combined with anlotinib in the management of retroperitoneal liposarcoma, particularly in cases where surgical options are limited.https://www.frontiersin.org/articles/10.3389/fonc.2025.1540868/fullliposarcomasurgeryrecurrenceiodine-125 seedsanlotinib |
| spellingShingle | Gaoyan Tang Yuping Zhang Wenjuan Meng Shoubin Zhong Hui Feng Guohua Yu Shuzhen Liu Rui Li Iodine-125 seeds combined with anlotinib in the treatment of recurrent retroperitoneal liposarcoma after surgery: a case report Frontiers in Oncology liposarcoma surgery recurrence iodine-125 seeds anlotinib |
| title | Iodine-125 seeds combined with anlotinib in the treatment of recurrent retroperitoneal liposarcoma after surgery: a case report |
| title_full | Iodine-125 seeds combined with anlotinib in the treatment of recurrent retroperitoneal liposarcoma after surgery: a case report |
| title_fullStr | Iodine-125 seeds combined with anlotinib in the treatment of recurrent retroperitoneal liposarcoma after surgery: a case report |
| title_full_unstemmed | Iodine-125 seeds combined with anlotinib in the treatment of recurrent retroperitoneal liposarcoma after surgery: a case report |
| title_short | Iodine-125 seeds combined with anlotinib in the treatment of recurrent retroperitoneal liposarcoma after surgery: a case report |
| title_sort | iodine 125 seeds combined with anlotinib in the treatment of recurrent retroperitoneal liposarcoma after surgery a case report |
| topic | liposarcoma surgery recurrence iodine-125 seeds anlotinib |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1540868/full |
| work_keys_str_mv | AT gaoyantang iodine125seedscombinedwithanlotinibinthetreatmentofrecurrentretroperitonealliposarcomaaftersurgeryacasereport AT yupingzhang iodine125seedscombinedwithanlotinibinthetreatmentofrecurrentretroperitonealliposarcomaaftersurgeryacasereport AT wenjuanmeng iodine125seedscombinedwithanlotinibinthetreatmentofrecurrentretroperitonealliposarcomaaftersurgeryacasereport AT shoubinzhong iodine125seedscombinedwithanlotinibinthetreatmentofrecurrentretroperitonealliposarcomaaftersurgeryacasereport AT huifeng iodine125seedscombinedwithanlotinibinthetreatmentofrecurrentretroperitonealliposarcomaaftersurgeryacasereport AT guohuayu iodine125seedscombinedwithanlotinibinthetreatmentofrecurrentretroperitonealliposarcomaaftersurgeryacasereport AT shuzhenliu iodine125seedscombinedwithanlotinibinthetreatmentofrecurrentretroperitonealliposarcomaaftersurgeryacasereport AT ruili iodine125seedscombinedwithanlotinibinthetreatmentofrecurrentretroperitonealliposarcomaaftersurgeryacasereport |